Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …

The heterogeneous nature of myelodysplastic syndromes (MDS) demands a complex and
personalized variety of therapeutic approaches. Among them, allogeneic hematopoietic …

PURPOSE Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a
don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by …

Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable
clinical presentations and outcomes. The initial response criteria developed by the …

PANTHER is a global, randomized phase 3 trial of pevonedistat+ azacitidine (n= 227) vs
azacitidine monotherapy (n= 227) in patients with newly diagnosed higher-risk …

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) is the only potentially
curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to …

Importance Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic
syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow …

Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Tet methylcytosine dioxygenase 2 (TET2) is one of the earliest and most frequently mutated
genes in clonal hematopoiesis of indeterminate potential (CHIP) and myeloid cancers …

Myelodysplastic syndromes (MDS) consist of a heterogeneous group of myeloid neoplasms
characterized by inefficient hematopoiesis, variable cytopenias and a considerable risk of …